This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Payen, S. Articles by Jacqz-Aigrain, E. Search for Related Content PubMed PubMed Citation Articles by Payen, S. Articles by Jacqz-Aigrain, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2005, p. 525-535, Vol. 49, No. 2
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.2.525-535.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Bayesian Parameter Estimates of Nelfinavir and Its Active Metabolite, Hydroxy-tert-Butylamide, in Infants Perinatally Infected with Human Immunodeficiency Virus Type 1

Salomé Payen,¹ Albert Faye,² Alexandra Compagnucci,³ Carlo Giaquinto,⁴ Diana Gibbs,⁵ Roberto Gomeni,^1, Françoise Bressolle,^1* and Evelyne Jacqz-Aigrain⁶

Laboratoire de Pharmacocinétique Clinique, Faculté de Pharmacie, Montpellier,¹ Département d'Hématologie,² Département de Pharmacologie Pédiatrique et Pharmacogénétique, Hôpital Robert Debré, Paris,⁶ Institut National de la Santé et de la Recherche Médicale (INSERM), Service Commun 10, Villejuif, France,³ Dipartimento de Pediatrica, Universita di Padova, Padua, Italy,⁴ MRC Clinical Trials Unit, London, United Kingdom⁵

Received 12 March 2004/ Returned for modification 24 May 2004/ Accepted 14 October 2004

The objective of the present study was to develop a population pharmacokinetic model for nelfinavir mesylate (NFV) and nelfinavir hydroxy-tert-butylamide (M8), the most abundant metabolite of NFV, in infants vertically infected with human immunodeficiency virus type 1 and participating in the Paediatric European Network for Treatment of AIDS 7 study. Plasma NFV concentrations were determined during repeated NFV administrations (two to three times a day). Eighteen infants younger that age 2 years participated in this study. The doses administered ranged from 71 to 203 mg/kg of body weight/day. Pharmacokinetic parameter estimates were obtained by a compartmental approach by using a kinetic model to simultaneously fit NFV and M8 (active metabolite) concentrations. M8 was shown to be formation rate limited and was characterized by first-order rate constants of formation and elimination. Body weight was found to be a more appropriate predictor than age of the changes in (i) the rate of metabolism, (ii) the elimination rate constant of NFV, and (iii) NFV clearance. Population parameters were computed to account for the relationship between the rate of metabolism and body weight. The estimated NFV and M8 elimination half-lives were 4.3 and 2.04 h, respectively. The estimated NFV clearance was 2.13 liters/h/kg. The M8 concentration-to-NFV concentration ratio was 0.64 ± 0.44. In conclusion, the population pharmacokinetic model describing the dispositions of NFV and M8 should facilitate the design of future studies to elucidate the relative contributions of the parent compound and M8 to the pharmacological and toxic effects of NFV therapy.

Present address: GlaxoSmithKline, Verona, Italy.

This article has been cited by other articles:

• Hirt, D., Urien, S., Jullien, V., Firtion, G., Rey, E., Pons, G., Blanche, S., Treluyer, J.-M. (2006). Age-Related Effects on Nelfinavir and M8 Pharmacokinetics: a Population Study with 182 Children. Antimicrob. Agents Chemother. 50: 910-916 [Abstract] [Full Text]